India has green-lighted molnupiravir for restricted emergency use in COVID-19, paving the way for the arrival of around a dozen generic versions of Merck & Co., Inc. and Ridgeback Biotherapeutics LP ‘s oral antiviral therapy in the country.
Wave Of Molnupiravir Generics In India Amid Early Physician Cheer
India authorizes molnupiravir for restricted emergency use in COVID-19, marking the arrival of around a dozen “affordable” generics of Merck & Co. and Ridgeback Biotherapeutics' oral antiviral. Physicians say data are “pretty compelling” notwithstanding the narrow FDA nod.
